Subthreshold laser therapy for diabetic macular edema: metabolic and safety issues.

Stela Vujosevic, Ferdinando Martini, Enrica Convento, Evelyn Longhin, Olympia Kotsafti, Raffaele Parrozzani, Edoardo Midena

Journal: Current medicinal chemistry 2014;20(26):3267-71

PMID: 23745552

Abstract

PURPOSE

To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).

METHODS

Review of the literature about the mechanisms of action and role of D-MPL in DME.

RESULTS

The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group.

CONCLUSIONS

MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.

Address: Department of Ophthalmology University of Padova, Padova, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.